Literature DB >> 10726241

Multiple sclerosis pathways: an innovative nursing role in disease management.

M G Madonna1, M M Keating.   

Abstract

Multiple sclerosis (MS), a chronic disease of the central nervous system, is characterized by a variable and unpredictable course. The most common pattern of the disease is the relapsing-remitting form in which clearly defined relapses (also called exacerbations) are followed by complete or incomplete recovery. Interferon beta-1b (Betaseron), a drug that affects the natural course of the disease, was developed for the treatment of relapsing-remitting MS. Multiple Sclerosis Pathways (MSP), a disease management program, was developed to provide comprehensive and personal support to MS patients taking interferon beta-1b and to serve as an information resource for all people with MS, their families, and healthcare professionals. The MSP program includes personal patient assistance, reimbursement services, a 24-hour nurse hotline, training program, educational resources, and injection supplies. The nurse hotline counselor (NHC) utilizes the nursing process in a unique telephone nursing practice in this program. The positive impact of education and support on adherence to therapy has been validated by training and nurse hotline data.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10726241     DOI: 10.1097/01376517-199912000-00003

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  2 in total

1.  Walgreens connected care: impact of managed therapy on adherence to medications used to treat multiple sclerosis and related comorbid conditions.

Authors:  Janeen DuChane; Bobby Clark; Francis Staskon; Rick Miller; Kathleen Love; Ian Duncan
Journal:  Int J MS Care       Date:  2015 Mar-Apr

Review 2.  Telephone follow-up, initiated by a hospital-based health professional, for postdischarge problems in patients discharged from hospital to home.

Authors:  P Mistiaen; E Poot
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.